Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy

European Journal of Gynaecological Oncology

Volumn 33, Issue 1, 2012, Pages 62-67

  Demirci, S ^a   Ozsaran, Z ^a   Ozsaran, A ^a   Yavas, F ^a   Demircioglu, B ^a   Hanhan, M ^b   Dikmen, Y ^a   Aras, A B ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Oncology Department   (Turkey)

Author keywords

Cervical cancer; Metastatic lymph node ratio; Prognostic factors; Radiochemotherapy; Radiotherapy; Side effects

Indexed keywords

CISPLATIN; HEMOGLOBIN; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; ENDOMETRIUM; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84860546675     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Landoni F., Maneo A., Colombo A., Plaga F., Milani R., Perego P. et al.: "Randomised study of radical surgery versus radiotherapy for Stage Ib-IIa cervical cancer". Lancet, 1997, 350, 535.
2. Halperin E.C., Perez C.A., Brady L.W.: "Perez and Brady's Principles and Practice of Radiation Oncology". 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.
3. Rotman M., Sedlis A., Piedmonte M.R., Bundy B., Lentz S.S., Muderspach L.I., Zaino R.J.: "A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study". Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 169.
4. Curtin J.P., Hoskins W.J., Venkatraman E.S., Almadrones L., Podratz K.C., Long H. et al.: "Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial". Gynecol. Oncol., 1996, 61, 3.
5. Grigsby P.W.: "Postoperative irradiation in cervical cancer: prognostic factors and outcome". Radiat. Med., 2004, 22, 106.
6. Beesley V., Janda M., Eakin E., Obermair A., Battistutta D.: "Lymphedema after gynecological cancer treatment : prevalence, correlates, and supportive care needs". Cancer, 2007, 109, 2607.
7. Montz F.J., Holschneider C.H., Solh S., Schuricht L.C., Monk B.J.: "Small bowel obstruction following radical hysterectomy: risk factors, incidence, and operative findings". Gynecol. Oncol., 1994, 53, 114.
8. Cox J.D., Stetz J., Pajak T.F.: "Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)". Int. J. Radiat. Oncol. Biol. Phys., 1995, 31, 1341.
9. Atahan I.L., Yildiz F., Ozyar E., Pehlivan B., Genc M., Kose M.F. et al.: "Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors". Int. J. Gynecol. Cancer, 2007, 17, 813.
10. Tsai C.S., Lai C.H., Wang C.C., Chang J.T., Chang T.C., Tseng C.J., Hong J.H.: "The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy". Gynecol. Oncol., 1999, 75, 328.
11. Ho C.M., Chien T.Y., Huang S.H., Wu C.J., Shih B.Y., Chang S.C. et al.: "Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy". Gynecol. Oncol., 2004, 93, 458.
12. Lai C.H., Hong J.H., Hsueh S., Ng K.K., Chang T.C., Tseng C.J. et al.: "Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases". Cancer, 1999, 85, 1537.
13. Aoki Y., Sasaki M., Watanabe M., Sato T., Tsuneki I., Aida H., Tanaka K.: "High-risk group in node-positive patients with Stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation". Gynecol. Oncol., 2000, 77, 305.
14. nd, Stock R.J., Monk B.J., Berek J.S. et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oncol., 2000, 18, 1606.
15. Kodama J., Seki N., Masahiro S., Kusumoto T., Nakamura K., Hongo A., Hiramatsu Y.: "Prognostic factors in Stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy". J. Surg. Oncol., 101, 413.
16. Piura B., Rabinovich A., Friger M.: "Surgical pathologic factors in patients with early-stage cervical carcinoma treated with radical hysterectomy and pelvic lymph node dissection: association with administration of adjuvant radiotherapy and effect on survival". Eur. J. Gynaecol. Oncol., 2006, 27, 573.
17. Sartori E., Tisi G., Chiudinelli F., La Face B., Franzini R., Pecorelli S.: "Early stage cervical cancer: adjuvant treatment in negative lymph node cases". Gynecol. Oncol., 2007, 107, S170.
18. Liu M.T., Hsu J.C., Liu W.S., Wang A.Y., Huang W.T., Chang T.H., Pi C.P., Huang C.Y. et al.: "Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy". Eur. J. Cancer Care (Engl.), 2008, 17, 174.
19. Qiu H.B., Zhang L.Y., Li Y.F., Zhou Z.W., Keshari R.P., Xu R.H.: "Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with Stage III colorectal cancer". Ann. Surg. Oncol., 2011, 18, 1568.
20. Showalter T.N., Winter K.A., Berger A.C., Regine W.F., Abrams R.A., Safran H. et al.: "The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704". Int. J. Radiat. Oncol. Biol. Phys., 2011, 81, 1328. Epub 2010 Oct. 8.
21. Polterauer S., Hefler L., Seebacher V., Rahhal J., Tempfer C., Horvat R. et al.: "The impact of lymph node density on survival of cervical cancer patients". Br. J. Cancer, 103, 613.
22. Benedetti Panici P., Basile S., Angioli R.: "Pelvic and aortic lymphadenectomy in cervical cancer: the standardization of surgical procedure and its clinical impact". Gynecol. Oncol., 2009, 113, 284.
23. Kesic V.: "Management of cervical cancer". Eur. J. Surg. Oncol., 2006, 32, 832.
24. Pieterse Q.D., Kenter G.G., Gaarenstroom K.N., Peters A.A., Willems S.M., Fleuren G.J., Trimbos J.B.: "The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer". Eur. J. Surg. Oncol., 2007, 33, 216.
25. Mayr N.A., Wang J.Z., Zhang D., Montebello J.F., Grecula J.C., Lo S.S. et al.: "Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer". Int. J. Radial. Oncol. Biol. Phys., 2009, 74, 1513.